Beam Therapeutics Inc. Interest and Other Income
Beam Therapeutics Inc. (BEAM) reported Interest and Other Income of $7.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-04
- Beam Therapeutics Inc. interest and other income for the quarter ending 2026-06-30 was $7.49M, a 39.26% decline year-over-year.
- Beam Therapeutics Inc. interest and other income for the quarter ending 2026-03-31 was $9.87M, a 0.03% increase year-over-year.
- Beam Therapeutics Inc. interest and other income for the quarter ending 2025-12-31 was $10.64M, a 2.64% decline year-over-year.
- Beam Therapeutics Inc. interest and other income for the quarter ending 2025-09-30 was $10.90M, a 10.09% decline year-over-year.
- Beam Therapeutics Inc. interest and other income for fiscal 2025 was $43.73M, a 10.92% decline from fiscal 2024.
- Beam Therapeutics Inc. interest and other income for fiscal 2024 was $49.09M, a 5.18% increase from fiscal 2023.
- Beam Therapeutics Inc. interest and other income for fiscal 2023 was $46.68M, a 205.13% increase from fiscal 2022.
- Beam Therapeutics Inc. interest and other income for fiscal 2022 was $15.30M.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.49M 10-Q · filed 2026-08-04 | $17.35M 10-Q · filed 2026-08-04 | $27.99M derived: sum of 3 quarters · filed 2026-08-04 | $38.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $9.87M 10-Q · filed 2026-05-07 | $20.51M derived: sum of 2 quarters · filed 2026-05-07 | $31.41M derived: sum of 3 quarters · filed 2026-05-07 | $43.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $21.54M derived: sum of 2 quarters · filed 2026-02-24 | $33.87M derived: sum of 3 quarters · filed 2026-08-04 | $43.73M 10-K · filed 2026-02-24 |
| 2025-09-30 | $10.90M 10-Q · filed 2025-11-04 | $23.23M derived: sum of 2 quarters · filed 2026-08-04 | $33.09M 10-Q · filed 2025-11-04 | $44.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $12.33M 10-Q · filed 2026-08-04 | $22.19M 10-Q · filed 2026-08-04 | $33.12M derived: sum of 3 quarters · filed 2026-08-04 | $45.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $9.86M 10-Q · filed 2026-05-07 | $20.79M derived: sum of 2 quarters · filed 2026-05-07 | $32.92M derived: sum of 3 quarters · filed 2026-05-07 | $47.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $23.05M derived: sum of 2 quarters · filed 2026-02-24 | $37.24M derived: sum of 3 quarters · filed 2026-02-24 | $49.09M 10-K · filed 2026-02-24 |
| 2024-09-30 | $12.13M 10-Q · filed 2025-11-04 | $26.32M derived: sum of 2 quarters · filed 2025-11-04 | $38.17M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $14.19M 10-Q · filed 2025-08-05 | $26.04M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $11.85M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $46.68M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $15.30M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |